NON-TECHNICAL PROJECT SUMMARY
Title of the project
Role of AQP4 in health and disease: Non channel functions of AQP4
NTS Identifier
NTS-NO-542122 v.1, 08-03-2024
NTS National Identifier
Field will not be published.
Country
Norway
Language
en
EU Submission
Field will not be published.
Yes
Project duration expressed in months.
49
Keywords
Aquaporin-4
Blood brain barrier
Brain
Rare mutation
Purpose(s) of the project
Basic research: Nervous System
Objectives and predicted benefits of the project
Describe the objectives of the project (for example, addressing certain scientific unknowns, or scientific or clinical needs).
AQP4 water channels have been shown to play an important role in development of brain edema following stroke, hyponatremia. However the physiological role of this protein is still controversial.We have evidence showing that AQP4 may be involved in the pathophysiology of several neurodegenerative disorders. Based on a newly described human mutation in the AQP4 gene, we have generated a mouse model with the same single mutation in AQP4 gene (generated by Transgensenteret, IMB) using CRISPR CAS9 technology. This animal model is the first model of a human disease causing mutation in the Aqp4 gene, where the one known patient internationally exhibits intellectual disability, ataxia and progressive motor loss. The gene affected encodes a water channel highly expressed in brain and is of relevance to a number of neurological conditions. Interestingly, it has been shown that the mutation does not affect the water permeability of AQP4, and thus modeling this mutation enables us to study the potential non-channel functions of AQP4, which are involved in neuroinflammation, possibly through an interaction with other brain cell types such as microglia. We are currently performing transcript and protein analysis. The preliminary results show that the mutation affects the protein expression level of AQP4, and also affects the expression of other proteins. We plan to analyze data from both young and aged animals, as the patient has a progressive clinical course. We want to continue heterozygous breeding and investigating this model the following years. We will use organs from the animals ex-vivo, either post perfusion fixation or post decapitation for protein and mRNA expression studies. The main aim of this project is: animal breeding and study on brain and other organs ex-vivo (immunohistochemistry, Western blotting and qPCR).
What are the potential benefits likely to derive from this project? Explain how science could be advanced, or humans, animals or environment may ultimately benefit from the project. Where applicable, differentiate between short-term benefits (within the duration of the project) and long-term benefits (which may accrue after the project is finished).
The study has the potential of identifying new functions of AQP4 and enabling our understanding of possible targets for therapy in conditions where AQP4 are involved, such as stroke, Parkinson's disease and neuroinflammatory conditions.
Predicted harms
In what procedures will the animals typically be used (for example, injections, surgical procedures)? Indicate the number and duration of these procedures.
Either deep anesthesia through i.p. injection of ZRF-cocktail prior to transcardial perfusion fixation, or cervical dislocation and decapitation. We will send additional information or separate applications when in vivo experiments (where surgery or other experiments on live animals is needed)
What are the expected impacts/adverse effects on the animals, for example pain, weight loss, inactivity/reduced mobility, stress, abnormal behaviour, and the duration of those effects?
NON-harmful genotype is expected, so genetic alteration will not be considered to cause any abnormalities in welfare of animals.
What species and numbers of animals are expected to be used? What are the expected severities and the numbers of animals in each severity category (per species)?
Species
Total number
Estimated numbers per severity
Non recovery
Mild
Moderate
Severe
Mice (Mus musculus)
650
0
650
0
0
What will happen to the animals kept alive at the end of the procedure?
Species
Estimated numbers of animals to be reused, to be returned to habitat/husbandry system or to be rehomed
Reused
Returned
Rehomed
Please provide reasons for the planned fate of the animals after the procedure.
Our experiments are ex vivo and therefore they must be terminated for organ harvesting.
Application of the Three Rs
1. Replacement
State which non-animal alternatives are available in this field and why they cannot be used for the purposes of the project.
In order to study the effect of the mutation on the mammalian nervous system, the use of experimental animals cannot currently be replaced. We have considered other model organisms, however in order to study the mutation on a evolutionary level relevant to humans, a mammalian model is necessary. Mice are the most suitable alternative.
2. Reduction
Explain how the numbers of animals for this project were determined. Describe steps that have been taken to reduce the number of animals to be used, and principles used to design studies. Where applicable, describe practices that will be used throughout the project to minimise the number of animals used consistent with scientific objectives. Those practices may include e.g. pilot studies, computer modelling, sharing of tissue and reuse.
We plan to reduce the number of animals used by several approaches: - Careful regional dissection is a method well established in our lab, that yields several samples from each brain to investigate different brain regions, further minimizing the sacrifice of animals - Each sample is extracted and stored in an optimized manner, enabling many investigations from one sample. We also take care to use the minimum amount of sample per experiment to extend the usefulness of each sample.
3. Refinement
Give examples of the specific measures (e.g., increased monitoring, post-operative care, pain management, training of animals) to be taken, in relation to the procedures, to minimise welfare costs (harms) to the animals. Describe the mechanisms to take up emerging refinement techniques during the lifetime of the project.
We ensure optimal anesthesia and humane treatment of animals in line with ethical regulations. We do our best to house animals together and not alone when possible, for example by placing single females together and use single males quickly or terminate. The animals live in a secure and enriched environment in the animal facility.
Explain the choice of species and the related life stages.
Mice has a enormous potential in being used to make all kinds of animal models for human genetic disorders through the use of CRIPR/Cas9-technology. We will primarily use the adult or old animals for our experiments. We will utilize adult animals for collection of brain samples for microscopy, protein and RNA analysis.
Project selected for Retrospective Assessment
Project selected for RA?
No
Deadline for RA
Reasons for retrospective assessment
Contains severe procedures
Uses non-human primates
Other reason
Explanation of the other reason for retrospective assessment
Additional fields
National field 1
Field will not be published.
National field 2
Field will not be published.
National field 3
Field will not be published.
National field 4
Field will not be published.
National field 5
Field will not be published.
Project start date
Field will not be published.
Project end date
Field will not be published.
Project approval date
Field will not be published.
ICD code 1
Field will not be published.
ICD code 2
Field will not be published.
ICD code 3
Field will not be published.
Link to the previous NTS version outside the EC system